**Chapter 2**

*Management of Dyslipidemia*

2020;382(16):1520-1530.

[51] Raal F, Kallend D, Ray K, et al. Inclisiran for Heterozygous Familial Hypercholesterolemia. N Engl J Med.

[52] Ray K, Wright R, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519.

[53] Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll

[54] Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration, Sarwar N,

Butterworth AS, et al. Triglyceridemediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-1639.

[55] Bhatt DL, Steg PG, Miller M, Brinton EA, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med

[56] Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia:

pharmacotherapy to reduce

cardiovascular risk. Pharmacol Ther

[57] Accord Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med

Cardiol 2014;64:485-494.

Sandhu MS, Ricketts SL,

2019;380:11-22.

2010;126:314345.

2010;362:1563-1574.

[58] Digenio A, Dunbar RL, Alexander VJ, Hompesch M, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes

Care 2016;39:1408-1415.

**20**
